Taysha Gene Therapies is trading 5.01% down at $4.26, with no clearly reported catalyst identified for the October 12 move.
- No new company-specific announcement explaining the move was identified; the latest updates were earlier announcements about employee inducement grants and planned Rett syndrome data presentations.
- The broader market was mixed, and available information does not establish a sector or macro event as the cause.